Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs Tango Therapeutics Inc. — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $34.64 (market cap $116.11M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 32.3× Roundhill NVDA WeeklyPay ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill NVDA WeeklyPay ETF for 52 Days and Tango Therapeutics Inc. for 0 Days on average.
| NVDW | TNGX | |
|---|---|---|
Market Cap | $116.11M | $3.75B |
Volume | 41,612 | 9,619,106 |
Sector | Income / Options Overlay | Health |
52-Week High | $52.33 | $32.90 |
52-Week Low | $31.88 | $7.50 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDW trades at $36.64 with minimal daily movement (+0.14%). Technical indicators show a bearish trend with strong sell signals from moving averages, though RSI suggests potential oversold conditions. The ETF generates weekly dividend income from Nvidia exposure but carries leverage risks. Recent news highlights its high-yield potential amid Nvidia's strong earnings performance.
The outlook remains cautious due to leveraged structure and dependency on Nvidia volatility. While weekly dividends offer income appeal, NAV erosion during Nvidia downturns presents significant risk. Investors should weigh high yield potential against elevated volatility exposure in this specialized income vehicle.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
